Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies

被引:17
|
作者
Hager, ACM [1 ]
Ellmark, P [1 ]
Borrebaeck, CAK [1 ]
Furebring, C [1 ]
机构
[1] Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden
关键词
D O I
10.1046/j.1365-3083.2003.01271.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and interfering antibodies have been suggested as an effective approach for the treatment of lymphomas and autoimmune diseases. In this study we have profiled a panel of mouse antihuman CD40 monoclonal antibodies (MoAbs), regarding their CD40 binding affinity and epitope-specificity relative to the CD40L binding in relation to their cellular activating potential. Despite a rather similar domain-recognition profile, the MoAbs blocked the CD40L binding to a varying degree, with MoAb 5C3 being the poorest inhibitor. There was no correlation between affinity and cellular activation potential. In contrast, a correlation between the ability to block CD40L-binding and activation potential could be seen. We believe that this analysis of several mouse anti-CD40 antibodies can be used to develop strategies for producing new human anti-CD40 antibodies that can more effectively induce or block B-cell proliferation.
引用
收藏
页码:517 / 524
页数:8
相关论文
共 50 条
  • [41] Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
    Ishihara, Jun
    Ishihara, Ako
    Potin, Lambert
    Hosseinchi, Peyman
    Fukunaga, Kazuto
    Damo, Martina
    Gajewski, Thomas F.
    Swartz, Melody A.
    Hubbell, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (11) : 2399 - 2411
  • [42] Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells:: the Janus face of anti-CD40
    de Herve, MGD
    Durali, D
    Tran, TA
    Maigné, G
    Simonetta, F
    Leclerc, P
    Delfraissy, JF
    Taoufik, Y
    BLOOD, 2005, 106 (08) : 2806 - 2814
  • [43] Identification of Fc mutations that optimize agonistic activity of human anti-CD40 monoclonal antibodies by enhancing appropriate Fcg receptor interactions
    Ye, Shiming
    Cohen, Diane
    Choi, Donghee
    Tan, Siu Sze
    Xiong, Joanna
    Akamatsu, Yoshiko
    Chao, Debra
    Hollenbaugh, Diane
    Harding, Fiona
    CANCER RESEARCH, 2018, 78 (13)
  • [44] The use of an anti-CD40 agonist monoclonal antibody during immunizations enhances hybridoma generation
    Rycyzyn, Michael A.
    Staquet, Kimberly
    Fisher, Jamie
    Bannish, Gregory
    Bassiri, Ashlyn
    Duchala, Cindy
    Giles-Komar, Jill
    HYBRIDOMA, 2008, 27 (01): : 25 - 30
  • [45] Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: Evidence of preclinical efficacy.
    Or, R
    Ackerstein, A
    Morecki, S
    Gelfand, Y
    Samuel, S
    Slavin, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 182S - 182S
  • [46] Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
    Martin, Cameron
    Waghela, Suryakant D.
    Lokhandwala, Shehnaz
    Ambrus, Andy
    Bray, Jocelyn
    Vuong, Christina
    Vinodkumar, Vanitha
    Dominowski, Paul J.
    Rai, Sharath
    Mwangi, Duncan
    Foss, Dennis L.
    Mwangi, Waithaka
    PLOS ONE, 2017, 12 (01):
  • [47] Epitope mapping and binding. Affinity analysis of CD34 monoclonal antibodies (MABs).
    Ramanathan, R
    Bone, B
    Hoffman, R
    Chen, B
    BLOOD, 1995, 86 (10) : 1208 - 1208
  • [48] Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models
    Shoji, Takuhiro
    Saito, Ryuta
    Chonan, Masashi
    Shibahara, Ichiyo
    Sato, Aya
    Kanamori, Masayuki
    Sonoda, Yukihiko
    Kondo, Toru
    Ishii, Naoto
    Tominaga, Teiji
    NEURO-ONCOLOGY, 2016, 18 (08) : 1120 - 1128
  • [49] Precision Medicine in Graves' Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody
    Faustino, Larissa C.
    Kahaly, George J.
    Frommer, Lara
    Concepcion, Erlinda
    Stefan-Lifshitz, Mihaela
    Tomer, Yaron
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [50] A phase I humanized Anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Harrop, KL
    McDonald, M
    Drachman, JG
    BLOOD, 2005, 106 (11) : 723A - 723A